UPDATE: Bank Of America Initiates Horizon Therapeutics With Buy, $34 Target As Firm's Thesis Is Driven By 'tepro approval and favorable payer coverage for TED', 'Krystexxa (gout) continued execution of re-launch and read-across to tepro launch hurdles'